Medicinova SEC Filings

Gran Tierra Energy Inc. (GTE) filed a Form 4 reporting that Chief Operating Officer Sebastien Morin purchased 502 shares of common stock on 06/17/2025 at a converted price of US $6.11 per share.

The shares were acquired through the company’s Employee Stock Purchase Plan, a transaction exempt under Rules 16b-3(d) and 16b-3(c). After this purchase, Morin’s direct beneficial ownership increased to 21,218 shares. No dispositions or derivative transactions were reported.

Although the dollar value is modest (≈US $3,070), insider purchases are generally viewed as a signal of incremental confidence from management. The filing does not disclose any options, warrants, or other derivative positions, and contains no additional financial metrics or company-wide developments.

Medicinova, Inc. (MNOV) – Form 4 insider filing

On 17 June 2025, director Carolyn Beaver was granted an option to purchase 20,000 shares of Medicinova common stock. The option’s exercise price is $1.26 per share and it will expire on 16 June 2035.

The award vests in four equal installments of 5,000 shares on the following dates, contingent on continued board service:

• 30 Sep 2025
• 31 Dec 2025
• 31 Mar 2026
• 30 Jun 2026

Following this grant, Beaver reports beneficial ownership of 20,000 derivative securities and no change in non-derivative holdings was disclosed.

The transaction was coded “A” (grant) and filed as a single-reporting-person Form 4 on 20 June 2025. No 10b5-1 plan was indicated.

Investor takeaway: This appears to be a routine equity incentive award to align director interests with shareholders; the 20,000-share size is modest relative to Medicinova’s outstanding share count and therefore immaterial from a dilution standpoint.

Bank of Montreal (BMO) is offering Senior Medium-Term Notes, Series K – Callable Barrier Notes with Contingent Coupons due July 7, 2028. The notes are unsecured, not principal-protected and are linked to the worst performer of three U.S. equity benchmarks: the S&P 500 Index (SPX), the NASDAQ-100 Index (NDX) and the Russell 2000 Index (RTY).

Income profile. Investors are eligible to receive a monthly Contingent Coupon of 0.7917 % (≈ 9.50 % p.a.) provided the closing level of each index on an Observation Date is at least 70 % of its Initial Level (the “Coupon Barrier”). If any index is below its barrier, the coupon for that month is forfeited.

Issuer call feature. Beginning July 1, 2026 (one year post-settlement) BMO may redeem the notes in whole on any Observation Date. If called, holders receive par plus the contingent coupon due on the related payment date; no further payments are made.

Maturity payoff. If the notes are not called, principal repayment depends on index performance as of the July 3, 2028 Valuation Date:

• If the Final Level of every index is ≥ its 70 % Trigger Level, investors receive par plus the final coupon (if payable).
• If any index closes < 70 % of its Initial Level (a “Trigger Event”), repayment is par – (percentage decline of the Worst-Performing Index). Losses are one-for-one with the decline and can reach 100 % of principal.

Issue economics. • Expected pricing date: July 1, 2025 • Settlement: July 7, 2025 • Denomination: $1,000 • Price to public: 100 % • Agent’s commission: up to 0.95 % • Estimated initial value: $980.90 (not less than $930) • CUSIP: 06376EME9. The notes will not be listed on any exchange, and secondary liquidity will rely solely on BMO Capital Markets (BMOCM), which may act as market-maker but is under no obligation to do so.

Key risks highlighted. Investors face (1) credit risk of Bank of Montreal, (2) market risk from three equity indexes, (3) contingent income risk (coupons can be zero), (4) call/reinvestment risk once coupons become attractive to BMO, (5) downside participation to zero if the worst index falls ≥30 %, and (6) estimated value discount versus issue price due to hedging and distribution costs. The product is not FDIC or CDIC insured and is intended for sophisticated investors comfortable with equity-linked structured products.